| Heidi C Calipjo, MD | |
|
1057 Medical Park Dr, Suite A, Osage Beach, MO 65065-3000 | |
| (573) 302-3100 | |
| (573) 348-8279 |
| Full Name | Heidi C Calipjo |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 20 Years |
| Location | 1057 Medical Park Dr, Osage Beach, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720288236 | NPI | - | NPPES |
| P00867670 | Other | MO | RAIL ROAD MEDICARE |
| 135570025 | Other | MO | MEDICARE PTAN |
| 1720288236 | Medicaid | MO | |
| 2010024506 | Other | MO | MO LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 125-052442 (Illinois) | Secondary |
| 207Q00000X | Family Medicine | 2010024506 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lake Regional Home Health | Osage beach, MO | Home health agency |
| Lake Regional Health System | Osage beach, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lake Regional Health System | 9133026776 | 81 |
News Archive
Death rates among patients admitted to a Colorado trauma center appeared to decrease after the center's designation was upgraded, according to a report in the January issue of Archives of Surgery, one of the JAMA/Archives journals.
Urodynamix Technologies Ltd. (TSX VENTURE:URO) today reported its financial results for its fiscal second quarter ended June 30, 2009. The Company reported revenues of $21,871, a 70% decrease over the same quarter of the prior year. The Company's order backlog at June 30, 2009 was $92,576 compared to nil at the end of the comparative quarter June 30, 2008.
Biopure Corporation announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions."
On 13th December 2007 a revised version of the European Patent Convention (EPC) came into force. This new law, known as EPC2000, has a number of consequences for the pharmaceutical industry and the way in which patent applications are examined.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.
› Verified 2 days ago
| Entity Name | Lake Regional Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053581454 PECOS PAC ID: 9133026776 Enrollment ID: O20070511000147 |
News Archive
Death rates among patients admitted to a Colorado trauma center appeared to decrease after the center's designation was upgraded, according to a report in the January issue of Archives of Surgery, one of the JAMA/Archives journals.
Urodynamix Technologies Ltd. (TSX VENTURE:URO) today reported its financial results for its fiscal second quarter ended June 30, 2009. The Company reported revenues of $21,871, a 70% decrease over the same quarter of the prior year. The Company's order backlog at June 30, 2009 was $92,576 compared to nil at the end of the comparative quarter June 30, 2008.
Biopure Corporation announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions."
On 13th December 2007 a revised version of the European Patent Convention (EPC) came into force. This new law, known as EPC2000, has a number of consequences for the pharmaceutical industry and the way in which patent applications are examined.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heidi C Calipjo, MD Po Box 1500, Osage Beach, MO 65065-1500 Ph: () - | Heidi C Calipjo, MD 1057 Medical Park Dr, Suite A, Osage Beach, MO 65065-3000 Ph: (573) 302-3100 |
News Archive
Death rates among patients admitted to a Colorado trauma center appeared to decrease after the center's designation was upgraded, according to a report in the January issue of Archives of Surgery, one of the JAMA/Archives journals.
Urodynamix Technologies Ltd. (TSX VENTURE:URO) today reported its financial results for its fiscal second quarter ended June 30, 2009. The Company reported revenues of $21,871, a 70% decrease over the same quarter of the prior year. The Company's order backlog at June 30, 2009 was $92,576 compared to nil at the end of the comparative quarter June 30, 2008.
Biopure Corporation announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions."
On 13th December 2007 a revised version of the European Patent Convention (EPC) came into force. This new law, known as EPC2000, has a number of consequences for the pharmaceutical industry and the way in which patent applications are examined.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.
› Verified 2 days ago
Samuel Brayfield, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5816 Osage Beach Pkwy, Suite 108, Osage Beach, MO 65065 Phone: 573-636-3313 Fax: 573-636-5881 | |
Dr. John Carlyn Brand, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1057 Medical Park Dr, Osage Beach, MO 65065 Phone: 573-302-3100 Fax: 573-348-8279 | |
Dr. Gina Renee Carter, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 940 Executive Dr, Lake Cboc-va, Osage Beach, MO 65065 Phone: 573-302-7890 Fax: 573-302-7974 | |
Dr. Mark W. Shen, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1057 Medical Park Dr, Suite A, Osage Beach, MO 65065 Phone: 573-348-2745 Fax: 573-348-8279 | |
Dr. Randall C Barnes, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1057 Medical Park Dr, Suite A, Osage Beach, MO 65065 Phone: 573-302-3200 Fax: 573-302-3210 | |
Kayla Colleen Reeves, FNP-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1029 Nichols Rd Ste 301, Osage Beach, MO 65065 Phone: 573-302-2864 | |
Rod Troy Barton, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1036 Indian Pointe, Osage Beach, MO 65065 Phone: 417-839-5240 |